Skip to main content
Log in

Comprehensive Case Management Models for Pulmonary Tuberculosis

  • Review Article
  • Published:
Disease Management & Health Outcomes

Abstract

In view of sweeping health and human service reforms around the US and abroad, program performance standards, their measurement, and their application in program accountability have become critical functions. Measuring the performance of healthcare systems has added a new dimension to the evaluation and management of acute care. Multiple-level evaluation approaches — including randomized controlled trials, cohort, case control and retrospective studies, economic modeling and cost-effectiveness analyses, and case studies — will be necessary to persuade diverse groups of stakeholders, particularly when the interventions are multi-faceted. The goal of multi-level evaluation approaches is to develop an internally consistent set of findings that produce a preponderance of evidence in support of a particular management strategy. Such an approach should also eliminate alternative explanations.

The management of certain infectious diseases such as pulmonary tuberculosis (TB) has refocused the attention of performance evaluators upon the concept of continuum of care. Multiple-level evaluation approaches consistently underscore a case management approach based on the use of comprehensive, community-based, patient-centered directly observed therapy (DOT) programs for achieving the highest treatment completion rates for patients with pulmonary TB.

As lengths of stays in hospitals continue to shorten, it has become apparent that clinical outcomes cannot be measured during the hospitalization episode(s) alone. This paper discusses the evidence-based case management of pulmonary TB, concluding that patient-centered approaches involving DOT provide the most effective care and disease prevention. Health and public healthcare systems should adopt such patient-centered approaches when managing resurgent infectious diseases such as pulmonary TB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Moore RD, Chaulk CP, Griffiths R, et al. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996 Oct; 154 (4 Pt 1): 1013–9

    PubMed  CAS  Google Scholar 

  2. Davis MS. Variations in patients’ compliance with doctors’ orders: analysis of congruence between survey responses and results of empirical investigations. J Med Educ 1966 Nov; 41(11): 1037–48

    PubMed  CAS  Google Scholar 

  3. Rubel AJ, Garro LC. Social and cultural factors in the successful control of tuberculosis. Pub Health Rep 1992; 107: 626–36

    CAS  Google Scholar 

  4. Bloom BR, Murray CJL. Tuberculosis: commentary on a re-emergent killer. Science 1992; 257: 1055–64

    Article  PubMed  CAS  Google Scholar 

  5. Tuberculosis Program Management in the United States 1986–1991. Atlanta (GA): Centers for Disease Control and Prevention, 1993

  6. Bloch AB, Cauthen GM, Simone PM, et al. Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis 1999 Apr; 3(4): 273–80

    PubMed  CAS  Google Scholar 

  7. Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. Lancet 1994 Mar 12; 343(8898): 647–8

    Article  PubMed  CAS  Google Scholar 

  8. Improving patient adherence to tuberculosis treatment. Rev ed. Atlanta (GA): Centers for Disease Control and Prevention, US Department of Health and Human Services, Public Health Services, 1994

  9. Zwarenstein M, Schoeman JH, Vundule C, et al. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998; 352(9137): 1340–3

    Article  PubMed  CAS  Google Scholar 

  10. Practice guidelines for public health: assessment of scientific evidence, feasibility and benefits: a report of the guidelines development project for public health practice. Albany (NY): Council on Linkages Between Academia and Public Health Practice, 1995 Oct

  11. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998 Mar 25; 279(12): 943–8

    Article  PubMed  CAS  Google Scholar 

  12. El-Sadr W, Medard F, Berthaud V, et al. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health 1996 Aug; 86 (8 Pt 1): 1146–9

    Article  PubMed  CAS  Google Scholar 

  13. Chaulk CP, Moore-Rice K, Rizzo R, et al. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995 Sep 27; 274(12): 945–51

    Article  PubMed  CAS  Google Scholar 

  14. Chaulk P, Kazandjian VA. Setting performance measures for public health ac-countabililty. In: Kazandjian VA, editor. Accountability through measurement: a global healthcare imperative. Milwaukee ((WI)): ASQ Quality Press, 2002: 270–90

    Google Scholar 

  15. Burman WJ, Dalton CB, Cohn DL, et al. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997 Jul; 112(1): 63–70

    Article  PubMed  CAS  Google Scholar 

  16. Palmer CS, Miller B, Halpern MT, et al. A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis. J Public Health Manag Pract 1998 May; 4(3): 1–13

    PubMed  CAS  Google Scholar 

  17. Chaulk CP, Friedman M, Dunning R. Modeling the epidemiology and economics of directly observed therapy in Baltimore. Int J Tuberc Lung Dis 2000 Mar; 4(3): 201–7

    PubMed  CAS  Google Scholar 

  18. Manalo F, Tan F, Sbarbaro JA, et al. Community-based short-course treatment of pulmonary tuberculosis in a developing nation: initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990 Dec; 142 (6 Pt 1): 1301–5

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Ms Dana Bonistalli, Executive Assistant, Center for Performance Sciences, for her assistance in the preparation and editing of the document.

The authors received no funding for this review and have no conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Patrick Chaulk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaulk, P., Kazandjian, V.A. Comprehensive Case Management Models for Pulmonary Tuberculosis. Dis-Manage-Health-Outcomes 11, 571–577 (2003). https://doi.org/10.2165/00115677-200311090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200311090-00005

Keywords

Navigation